Renaissance Capital logo


US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week


The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), more

Rare disease biotech Rallybio prices IPO at $13 low end

Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, raised $81 million by offering 6.2 million shares at $13, the low end of the range of $13 to $15. The company offered 0.5 million more shares than anticipated. Rallybio is currently advancing its lead program, RLYB211, in a Phase 1/2 trial for the treatment of fetal and neonatal more

US IPO Week Ahead: Robinhood’s billion-dollar deal headlines a 25 IPO week


Updated Monday, 7/26. After another week of record activity, the IPO market is expected to remain hot with 25 IPOs scheduled for the week ahead. If all scheduled IPOs begin trading as expected, it would be the busiest week for the US IPO market in more than two decades. Long-awaited retail brokerage Robinhood Markets (HOOD) plans to raise $ more

Rare disease biotech Rallybio sets terms for $81 million IPO

Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday. The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Rallybio would command a fully diluted market value of $465 million. Rallybio is currently more